-+ 0.00%
-+ 0.00%
-+ 0.00%

Autonomix Medical To Present At TCT 2025 Conference Showcasing Initial Results From Its First-in-Human Study On Transvascular Nerve-Targeted Therapy To Reduce Pancreatic Cancer Pain

Benzinga·10/24/2025 13:05:40
Listen to the news

Autonomix Medical, Inc. (NASDAQ:AMIX) ("Autonomix" or the "Company"), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced it will be featured in two podium presentations at the Transcatheter Cardiovascular Therapeutics® (TCT®) Annual Scientific Conference (TCT 2025) being held October 25-28, 2025 in San Francisco, CA.

The presentations will highlight positive results from the initial phase of Autonomix's first-in-human proof-of-concept clinical study evaluating the safety and effectiveness of delivering transvascular energy to ablate relevant problematic nerves and mitigate pain in patients with pancreatic cancer pain.